secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001493152-22-034614
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TenX Keane Acquisition announces separate trading of ordinary shares and rights effective Dec 8, 2022
--------------------------------------------------------------------------------

- Holders of 6,600,000 units from IPO may elect to separate shares and rights starting Dec 8.
- Separated ordinary shares will trade under TENK; rights under TENKR; units continue as TENKU.
- Separation requires contacting transfer agent American Stock Transfer & Trust Company.
- No financial terms, business combination, or change in strategy announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000149315222034614/0001493152-22-034614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000149315222034614/from8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-034614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer